The Uptake Of Key Agents Such As Januvia, Bydureon And Byetta Will Drive The Type 2 Diabetes Drug Market To Increase From $19 Billion To $36 Billion

Podiatry Arena The Uptake Of Key Agents Such As Januvia, Bydureon And Byetta Will Drive The Type 2 Diabetes Drug Market To Increase From $19 Billion To $36 Billion

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

The Uptake Of Key Agents Such As Januvia, Bydureon And Byetta Will Drive The Type 2 Diabetes Drug Market To Increase From $19 Billion To $36 Billion

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

22nd September 2010, 09:20 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,130

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 22 Times in 22 Posts

The Uptake Of Key Agents Such As Januvia, Bydureon And Byetta Will Drive The Type 2 Diabetes Drug Market To Increase From $19 Billion To $36 Billion

Podiatry Arena members do not see these ads

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United Stat...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes	RSSFeedBot	Latest Diabetes Medicine Research & News	0	31st October 2009 06:10 AM
Surveyed Experts Indicate That Byetta LAR And Victoza Have Advantages Over Actos In The Treatment Of Type 2 Diabetes	RSSFeedBot	Latest Diabetes Medicine Research & News	0	25th March 2009 07:10 AM
Australia's Wake-Up Call - Obesity Costs Now At $58 Billion Type 2 Diabetes Crisis	RSSFeedBot	Latest Sports Medicine News	0	25th August 2008 03:20 AM
World Foot Care Products Market to Reach $3.4 Billion by 2010	NewsBot	General Issues and Discussion Forum	0	28th April 2008 05:09 AM
Diabetic foot ulcer market worth $1.5 billion	NewsBot	Diabetic Foot & Wound Management	0	31st October 2007 01:57 PM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 08:11 AM.

User Name		Remember Me?
Password